Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

U.S. plans to begin administering COVID-19 booster shots in September - source

Published 08/16/2021, 10:55 PM
Updated 08/17/2021, 04:25 AM
© Reuters. FILE PHOTO: A large vaccination site is shown as people with preexisting health conditions are granted access to a vaccination during the outbreak of the coronavirus disease (COVID-19) in Inglewood, California, U.S., March 15, 2021.  REUTERS/Mike Blake
PFE
-
JNJ
-
MRNA
-
BNTX
-

(Reuters) -The Biden administration plans to begin administering COVID-19 booster shots to Americans as early as mid or late September, pending authorization from the U.S. Food and Drug Administration, a source familiar with the discussions told Reuters late on Monday.

Health officials in U.S. President Joe Biden's administration gathered round the view that most people should get a booster shot eight months after they completed their initial vaccination, the source said.

According https://nyti.ms/3spoZiU to the New York Times, which earlier reported the development, officials are planning to announce the administration's decision as early as this week, with the first boosters likely to go to nursing home residents and health care workers, followed by other older people.

Last week, U.S regulators authorized a third dose of COVID-19 vaccines by Pfizer Inc (NYSE:PFE) and its German partner BioNTech SE (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) Inc for people with compromised immune systems who are likely to have weaker protection from the two-dose regimens.

© Reuters. FILE PHOTO: A large vaccination site is shown as people with preexisting health conditions are granted access to a vaccination during the outbreak of the coronavirus disease (COVID-19) in Inglewood, California, U.S., March 15, 2021.  REUTERS/Mike Blake

The administration's goal is to let those who received the Pfizer-BioNTech or Moderna vaccines know that they will need additional protection against the Delta variant of the coronavirus, NYT said.

The newspaper added that officials also expect recipients of the vaccine from Johnson & Johnson (NYSE:JNJ), which was authorized as a one-dose regimen, will also require an additional dose.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.